Nasopharyngeal cancer WHO type II-III: Monoinstitutional retrospective analysis with standard and accelerated hyperfractionated radiation therapy

G. Franchin, E. Vaccher, R. Talamini, C. Gobitti, E. Minatel, D. Politi, G. Sartor, M. G. Trovò, L. Barzan

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this study is to assess the impact of prognostic factors in patients with locoregionally advanced nasopharyngeal cancer (NPC), WHO type II-III, treated with two different radiation therapy (RT) schedules: standard radiation therapy (SRT), and accelerated hyperfractionated radiation therapy (HART), with or without sequential chemotherapy. Between January 1986 and December 1999, 78 consecutive NPC patients were treated either with SRT (until August 1993) or with HART (from September 1993). Of the 78 patients, 60 were males and 18 females, the median age was 56 years (range 14-83). Nine patients had a non-keratinizing carcinoma (WHO type II) and 69 an undifferentiated carcinoma (WHO type III). Five-year overall survival rate (OS) was 62%. Two months after RT, 73 patients were in complete remission. Disease-free survival (DFS) rates at 5 years were: 85% for the HART and 59% for the SRT group, respectively. A multivariate analysis, age (hazard ratio, HR = 4.17 for ≥ 60 vs.

Original languageEnglish
Pages (from-to)137-144
Number of pages8
JournalOral Oncology
Volume38
Issue number2
DOIs
Publication statusPublished - 2002

Keywords

  • Accelerated hyperfractionated radiation therapy
  • Nasopharyngeal carcinoma WHO type II-III
  • Neoadjuvant chemotherapy

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Nasopharyngeal cancer WHO type II-III: Monoinstitutional retrospective analysis with standard and accelerated hyperfractionated radiation therapy'. Together they form a unique fingerprint.

Cite this